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ackground: The incidence of multiple drug resistance tuberculosis is on the rise worldwide and Pakistan 
is one of 30 high TB burden countries. Resistance to second line drugs especially fluoroquinolones is 
being reported by many laboratories. This is increasing the gravity of the situation resulting in extensively 
drug resistant cases, which is difficult to treat, and has more side effects.  
Methods: One hundred and thirty-three (133) clinical isolates of M. tuberculosis, collected by convenience 
sampling, were characterized for mutations in eth-A, gyrA, msh-A, rrs genes, and the promoter region of inh-A 
gene that confer resistance to second line anti-TB drugs. The mutations were detected by allele-specific-PCR 
and PCR amplification followed by SSCP and DNA sequencing.  
Results: Mutations in gyrA gene at codon 91, 94 and 95 were found in 4 (3.0%) M. tuberculosis isolates. 
Mutations in rrs gene were found in 17 (12.8%) isolates, ten (7.5%) isolates had mutation at A1401G position, 5 
(3.76%) isolates at C1402T position and 3 (2.25%) isolates had G1484T mutation. For resistance to ethionamide, 
none of the isolates showed mutation in eth-A gene. In promoter region of inh-A gene, mutations were detected 
at -C15T, -A112G, -C110T in two samples. Two mutations, A312T and A332G, were found in msh-A gene in 
one sample. Collectively, 24 (18%) isolates were found to harbor mutations associated with second line anti TB 
drug resistance. 
Conclusion: Our work revealed high frequency of mutations (18%) associated with resistance against second 
line anti-TB drugs. This situation can lead to increase in XDR-TB cases. We, therefore, recommend improved 
diagnostic and drug sensitivity testing, better prescription, and development of superior drugs to control 
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Introduction  
Tuberculosis (TB) is an air born disease caused by 
Mycobacterium tuberculosis (M. tuberculosis). Mostly, it 
affects lungs (pulmonary TB) but other sites of the body 
could also get affected causing extrapulmonary TB. It is 
one of the top 10 causes of death worldwide with an 
estimated 10.0 million incident cases and 1.2 million 
deaths. According to World Health Organization report of 
2020, drug resistant tuberculosis is continuously a public 
health threat and is obstacle to TB care and prevention. 
The incident of rifampicin-resistant TB (RR-TB) in 2019 
is reported to be half a million people, of which 78% had 
multidrug resistant TB (MDR-TB) [1]. MDR-TB is defined 
as resistance to rifampicin (RIF) and isoniazid (INH) with 
or without resistance to the other first-line anti-TB drugs. 
On the other hand, incident of extensively drug resistant 
TB (XDR-TB) accounts 7.4% of MDR-TB globally [2]. 
XDR-TB is defined as MDR-TB with resistance to any 
fluoroquinolones and at least one of the second-line 
injectable – amikacin, capreomycin or kanamycin anti-
TB drugs. The actual incidence may be higher than the 
reported cases because many low and lower middle-
income countries do not have adequate capability to test 
for resistance to second-line drugs and thus to detect 
XDR-TB. 
Pakistan ranks 5th among 8 “high TB burden” countries 
having two third of all estimated incident cases 
worldwide. According to National TB Control Program, 
580,000 new cases of all forms of TB are reported 
annually with 50,000 deaths. Moreover, there are 
estimated 28,000 reported cases of MDR-TB where only 
11% of them were diagnosed and treated [3]. These 
patients will receive second line anti-TB drug therapy 
including fluoroquinolones (FQ), a vital component of 
drug regimen for MDR cases. Treatment of MDR-TB is 
more challenging as it relies on prolonged use of second 
line anti-TB drugs while XDR-TB treatment is further 
hampered by use of more toxic, less effective and 
expensive anti-TB drugs including use of longer duration 
of injectable drugs. Recently, van der Heijden et.al., [4] 
has reported an increase in FQ resistance in anti TB 
treatment-naive TB patients that lead to increased 
mortality. 
Fluoroquinolones disrupt the function of gyrA and gyrB 
genes that consequently ceases bacterial growth. 
Mutations in these genes make these drugs ineffective 
against bacteria. The most commonly found missense 
mutations are at position 90, 91 and 94 in gyrA gene [5]. 
The second-line anti-TB drugs apart from FQ and 
streptomycin are aminoglycosides (capreomycin (CM), 
amikacin (AK), kanamycin (KM)) and ethionamide (ETA). 
Capreomycin is peptide in nature and inhibits protein 
synthesis by binding with 50S or 30S ribosomal RNA. 
Mutations in rrs gene and tly-A gene are associated with 
resistance against aminoglycosides. Ethionamide is a 
pro-drug which becomes active with the help of an 
enzyme, monooxygenase [6,7]. This enzyme is coded by 
the gene eth-A which is regulated by eth-R [8]. After 
activation, these drugs target the activity of ndh-A, inh-A 
and msh-A genes which are involved in the synthesis of 
bacterial cell wall.  
Drug susceptibility in M. tuberculosis strains is 
conventionally based on culture in liquid or solid media. 
Though it adequately detects RIF or INH resistance but 
is less reliable and complicated for second line anti-TB 
drugs [9]. Moreover, many developing countries do not 
have the resources to establish the facility for drug 
susceptibility testing for second line anti-TB drugs. 
These growth-based methods require weeks to months 
and the patients resistant to these drugs remain 
contagious and may die before they are treated with right 
medicines. Further, these infected and uncured patients 
remain a potent source of transmission of drug resistant 
form of disease in the community. The advent of 
molecular biology techniques that do not require 
culturing these slow-growing pathogens are helpful in the 
management of M/XDR-TB.  
We, hereby, report mutations associated with second 




In total, 133 M. tuberculosis isolates were collected by 
convenience sampling from TB patients belonging to 
different cities of Pakistan. Twenty-five culture isolates 
were collected from Armed Forces Institute of Pathology, 
seven from Mayo Hospital Lahore and six from TB 
hospital Faisalabad. DNA from ninety-five M. 
tuberculosis isolates was provided by Holy Family 
Hospital, Rawalpindi. Clinical specimens were cultured 
on Lowenstein Jenson (LJ) media. DNA extraction was 
performed using CTAB method [10]. 
PCR Amplification 
The primers were designed for the promoter region of 
inh-A gene and for the hot spot regions of msh-A and 
eth-A gene. The primers for the gyrA gene were retrieved 
from a previous study [11]. The primers for ASO-PCR of 
three most common mutations (A1401G, C1402T, 
G1484T) in rrs gene were also designed. Primers for all 
these targeted regions were synthesized based on NCBI 
reference sequence NC_000962.3 of M. tuberculosis 
H37Rv. The PCR primer sequences, annealing 
temperatures and the size of the amplification products 
are listed in table 1. PCR products were analyzed by 
agarose gel electrophoresis. 
Single stranded conformational polymorphism 
(SSCP) analysis 
PCR products of hotspot regions of gyrA, mshA, inhA, 
and eth-A genes were resolved on 7% polyacrylamide 
gel for single strand confirmation polymorphism (SSCP) 
analysis. The amplified hotspot regions of the isolates 
that showed mobility shift in SSCP analysis were 
sequenced commercially. 
Allele specific oligonucleotide (ASO) PCR analysis 
For the detection of most common mutations (A1401G, 
C1402T, G1484T) in rrs gene, ASO-PCR analysis was 
done. ASO-PCR amplification products were resolved by 
agarose gel electrophoresis. The relative absence or 
presence of the amplification with corresponding primers 
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suggested presence of wild type or mutant allele. The 
PCR primer sequences, annealing temperature and the 
size of the amplification products are listed in table 1. 
Primer Type of 
Primer 






GyrA Forward cagctacatcgactatgcga 320  45 
Reverse Atgaggtacaccgaagccc 
InhA-P Forward ctcgctgcccagaaaggga 248  60 
Reverse Atcccccggtttcctccggt 
Msh-A Forward gcggcatgaacgtctacatgct 346  60 
Reverse gccagcgtgtgtgcggtgt 





























Table 1: Primer Sequences used to amplify the targeted regions 
of selected genes. 
Ethical use statement 
Sample collection, experiments and data use were 
performed under institutional ethical guidelines. No 
personal details of the patients were disclosed. 
Results 
Fluoroquinolones 
Out of 133 isolates, 4 isolates showed mobility shift in 
SSCP analysis. Sequencing of these isolates revealed 
mutations, either singly or in combination, at codon 91, 
94 and 95 of gyrA gene. Hence, the frequency of 
mutations that confer fluoroquinolone resistance was 
found to be 3.0%. One isolate showed mutations in 
codons 94 and 95; at codon 94 nucleotide A is changed 
into G, which results in the replacement of aspartate with 
glycine, and at codon 95 where G is replaced by C, 
amino acid serine is replaced by threonine. One isolate 
harbored mutations at two different codons 91 and 95; at 
codon 91 nucleotide T is replaced by C and consequently 
serine is changed into proline and at codon 95 G is 
replaced by C, amino acid serine is changed into 
threonine. Two other isolates revealed mutation singly in 
codon 95 or in codon 94 (table 2). 
Ethionamide 
For resistance to ETA, the genes eth-A, msh-A, and 
complete promoter region of ih-A were characterized. 
Sequencing results of PCR products revealed no 
mutation in targeted fragment (418 bp) of eth-A gene. In 
promoter region of inhA gene -C15T, the most commonly 
reported mutation, was found in two isolates while two 
novel mutations (-A112G, -C110T) were observed in one 
isolate. Thus, collectively, 2.26% isolates showed 
mutation in promoter region of inh-A. DNA sequencing of 
346 bp region of msh-A gene revealed two mutations 
(A312T, A332G) in one (0.75%) isolate, and among 
these mutations A312T is a novel mutation (table 3). 
Collectively, we found 4/133 (3.0%) mutant isolates 
against ethionamide in inh-A and msh-A genes (Table 3). 
Aminoglycosides 
For amikacin, kanamycin and capreomycin drug 
resistance, three nucleotide positions were targeted by 
designing ASO primers. PCR and agarose gel 
electrophoresis results confirmed mutations in rrs gene. 
These mutations conferring resistance to 
aminoglycosides, were found in 12.8% (17/133) M. 
tuberculosis isolates. Ten isolates (7.5%) had mutation 
at A1401G, 5 isolates (3.76%) at C1402T position, and 3 
isolates (2.25%) had mutation at G1484T position. 
Among these, one sample showed mutations in two 
codons (A1401G and G1484T). We report the overall 
mutation frequency of 9.77% against amikacin and 
kanamycin and 13.53% against capreomycin in M. 
tuberculosis isolates (Table 4). 
Summary of results 
In total, we found 24 (18%) mutant isolates in msh-A, 
promoter region of inh-A, gyrA, and rrs gene, known to 
confer resistance against second line anti-TB drugs. This 
is an alarmingly high frequency of mutations in M. 
tuberculosis strains circulating presently among TB 
patients in Pakistan. This high frequency of mutations is 
leading to a disquieting increase in XDR-TB in Pakistan. 
In this study, four isolates were mutated in gyrA, two 
were mutated in inh-A, one in msh-A and 17 samples 
were found mutated in rrs gene (Table 5). 
Discussion 
Bio-plastic production has faced many setbacks due to 
Fluoroquinolones are an integral component of second-
line therapy for multidrug-resistant strains and its 
resistance is increasing in MDR-TB strains [11]. In the 
present study, the frequency of mutations in gyrA gene 
was 3.0%. All these mutations are missense and have 
already been reported [12]. Our results are in agreement 
to a previous report from Pakistan where 3.1% of 
isolates, susceptible to all first-line agents, were reported 
to be fluoroquinolone resistant [13]. The reason for this 
may be the extensive use of fluoroquinolones. The 
fluoroquinolones, being broad spectrum antibiotics, are 
used for treating several infectious diseases. Their easy 
administration and excellent gastrointestinal absorption, 
tissue penetration and lack of unwanted side effects [14] 
make them the drug of choice for many health 
practitioners. In Pakistan, fluoroquinolones are available 
to the general population as over-the-counter medicine 
and hence its misuse can lead to drug resistance. 
Moreover, in the absence of strict guidelines for 
treatment, the physicians overprescribe these drugs. 
Acquisition of de novo mutations in its target may have a 
selective pressure to develop FQ resistant bacteria and 
if this selective pressure extends beyond the targeted 
etiological agent, it may result in FQ resistant M. 
tuberculosis strains. Increase in FQ resistant M.  
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tuberculosis strains has also been reported from India 
(from 3% to 35%) [15] and Taiwan (from 7.7% to 20%) 
[16].  
Mutations in inh-A promoter region were found at three 
distinct positions where two mutations, -A112G, -C110T 
are novel. Similarly, DNA sequencing of msh-A revealed 
novel mutation at A312T. The role of these mutations in 
drug resistance needs to be elucidated by further 
studies. Similar mutations within the ethA and inhA 
structural genes that confer ethionamide resistance have 
been reported in 49.6% ethionamide resistant M. 
tuberculosis isolates from India [17], 76% from USA [8] 


















































mutation in rrs gene at targeted positions (A1401G, 
C1402T and G1484T). Mutations in rrs gene have been 
reported, in literature, at different nucleotide positions 
such as, T16G, T16A, C491T, C512T, A513C, C904A, 
G1302A [19] and 514, 517, 1401, 1402, 1443, 1473, 
1484, 152 [20]. A strong correlation has been reported 
between a mutation at position A1401G and the 
resistance to amikacin and kanamycin [21-23]. It is 
reported that the C1402T mutation in the rrs gene is 
associated with capreomycin resistance and the 
Gene Number of mutants Sample ID Change in 
nucleotide 
Codon number Change in codon Change in Amino Acids 
gyrA 4 TB-80 T271C S91P 
TCG CCG 
Ser to Pro 
G284C S95T 
AGC ACC 
Ser to Thr 
TB-82 A281G D94G 
GAC GGC 
Asp to Gly 
G284C S95T 
AGC ACC 
Ser to Thr 
TB-108 G284C S95T 
AGC ACC 
Ser to Thr 
TB-135 A281G D94G 
GAC GGC 
Asp to Gly 
Table 2: Mutations found in gyrA gene. The mutations were detected by allele-specific-PCR and PCR amplification followed by SSCP 
and DNA sequencing.  






Codon number Change in Codon Change in amino acids 
eth-A ---- ----- ----- ----- ----- ---- 
msh-A 1 TB-36 A312T A104A 
GCA GCT Ala Ala 
A332G N111S 








Table 3: Mutations found in eth-A, msh-A and promoter region of inh-A gene. The mutations were detected by allele-specific-PCR 
and PCR amplification followed by SSCP and DNA sequencing. 
Gene Sample 
ID 







TB-132 - C1402T - 
TB-140 A1401G - - 
TB-168 A1401G - - 
TB-200 A1401G - - 
TB-87 - C1402T - 
TB-90 - C1402T - 
TB-95 - - G1484T 
TB-96 A1401G - - 
TB-102 - - G1484T 
TB-116 A1401G - - 
TB-108 A1401G - G1484T 
TB-110 A1401G - - 
TB-122 - C1402T - 
TB-113 - C1402T - 
TB-117 A1401G - - 
TB-139 A1401G - - 
TB-141 A1401G - - 
Table 4:  Mutations found in rrs gene. The mutations were detected by allele-specific-PCR and PCR amplification followed by SSCP 
and DNA sequencing. “-“: This sign shows that this particular mutations is not present in corresponding isolate. 
Drug %age of mutated 
samples  




Change in nucleotide 
Ethionamide ----- eth-A ----- ----- ------ 
3/133 (2.25%) inhA-P 1.5% 2 -A112G,C 
-C110T 
-C15T 









rrs 7.5% 10 A1401G 
3.76% 5 C1402T 
2.25 % 3 G1484T 
Table 5: Drug-wise Summary of results. The mutations were detected by allele-specific-PCR and PCR amplification followed by SSCP 
and DNA sequencing. 
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mutation at G1484T is associated with amikacin, 
kanamycin and capreomycin resistance [24]. Based on 
our results, we can deduce that 9.77% isolates harbored 
mutations associated with amikacin and kanamycin 
resistance, and 13.53 % with capreomycin resistance. 
This high frequency of mutations emphasizes the need 
to design the personalized drug regimen for TB patients 
carefully, depending upon the drug sensitivity data. 
Molecular genotypic methods of drug sensitivity testing 
may be a better option and can complement the 
phenotypic DST results.  
At least 23 countries in Africa and Asia introduced 
shorter MDR-TB regimens, which have achieved high 
treatment success rates (87‒90%) under operational 
research conditions. Based on these studies, WHO now 
recommends a standardized shorter MDR-TB regimen 
for selected MDR/RR-TB patients who do not have 
resistance to fluoroquinolones or second-line injectable 
agents. In this scenario, it is important to detect the FQ 
sensitivity of individual patients before starting this more 
effective and shorter MDR-TB regimen. Genotypic 
detection of drug sensitivity may help prescribe the 
appropriate drug regimen for individual patients before 
the availability of phenotypic DST results. This may 
contribute in controlling transmission of drug-resistant 
TB. 
Our data shows high frequency of mutations in M. 
tuberculosis isolates circulating presently among TB 
patients in Pakistan. We are of the view that the MDR-
TB strains in patients starting second-line drug treatment 
are first tested for sensitivity to these drugs for timely and 
effective treatment of these patients and to ensure that 
resistance is not further amplified. This will decrease the 
incidence and spread of XDR-TB. If the sources allow, 
we recommend that at least drug sensitivity testing of 
fluoroquinolones and aminoglycosides should be 
included when the drug sensitivity against first line anti-
TB drugs is being done. Furthermore, genotypic drug 
sensitivity testing could be a better choice before starting 
therapy.  
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